2.26
전일 마감가:
$2.27
열려 있는:
$2.26
하루 거래량:
30,061
Relative Volume:
0.92
시가총액:
$68.90M
수익:
$300.00K
순이익/손실:
$-40.16M
주가수익비율:
-1.7155
EPS:
-1.3174
순현금흐름:
$-42.36M
1주 성능:
+0.44%
1개월 성능:
-3.00%
6개월 성능:
-16.61%
1년 성능:
-21.25%
Xbiotech Inc Stock (XBIT) Company Profile
명칭
Xbiotech Inc
전화
512-386-2900
주소
5217 WINNEBAGO LANE, AUSTIN, TX
Compare XBIT vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
XBIT
Xbiotech Inc
|
2.26 | 69.21M | 300.00K | -40.16M | -42.36M | -1.3174 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Xbiotech Inc Stock (XBIT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-06-14 | 개시 | Piper Jaffray | Overweight |
| 2017-04-21 | 다운그레이드 | Noble Financial | Buy → Hold |
| 2016-06-28 | 재확인 | Noble Financial | Buy |
Xbiotech Inc 주식(XBIT)의 최신 뉴스
XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
XBiotech Inc (XBIT) Balance Sheet - TradingKey
XBIT|XBiotech Inc|Price:2.260|Chg%:-0.010 - TradingKey
XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIT|XBiotech Inc|Price:2.270|Chg%:-0.010 - TradingKey
XBiotech, Inc. Actuals & Estimates (FWB:4XB) - TradingView
XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XBiotech Inc. Revenue Breakdown – NASDAQ:XBIT - TradingView
MSN Money - MSN
XBiotech (XBIT) Holds Steady at $2.29 as Range-Bound Trading ContinuesIPO Entry Watch - dars.gov.et
XBiotech Inc. (XBIT) Slides 2.97% as Shares Approach Key Support at $2.18Pairs Trade - dars.gov.et
XBiotech focuses on antibody pipeline as biotech sector evolves - Ad-hoc-news.de
ETFs Investing in XBiotech, Inc. Stocks - TradingView
XBiotech, Inc. Actuals & Estimates (SWB:4XB) - TradingView
XBiotech Inc. (XBIT) Holds Steady at $2.33 as Key Support and Resistance Levels ConvergeVolume Dry Up - dars.gov.et
XBiotech, Inc. Actuals & Estimates (LS:A14QF1) - TradingView
XBiotech, Inc. Actuals & Estimates (MUN:4XB) - TradingView
Price to earnings forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (NASDAQ:XBIT) - TradingView
Price to sales forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (DUS:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (BX:4XB) - TradingView
Enterprise value to revenue forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (BOATS:XBIT) - TradingView
Price to book forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
Enterprise value to EBIT forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech to commence V-SPINE trial enrolment for vilamakitug - MSN
XBiotech (XBIT) Dips 2.53% as Shares Test Support Near $2.19Motive Wave - dars.gov.et
XBiotech Inc. (XBIT) Nears Key Support After 2.5% DeclineAdvance Decline Volume - dars.gov.et
XBiotech Inc. (XBIT) Declines: Testing Key Support Levels After 2.53% DropHigh Beta Stocks - dars.gov.et
XBiotech Inc (XBIT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XBiotech Inc (XBIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XBiotech Inc (XBIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
XBiotech Inc (XBIT) Institutional Confidence - TradingKey
XBIT Earnings Overview 2026-06-16Profit Warning Alert - dars.gov.et
XBiotech Receives Authorization for V-SPINE Trial - Intellectia AI
XBiotech Inc Stock (US9840001002): FDA clears Phase II V-SPINE trial for vilamakitug in axial spondy - AD HOC NEWS
XBiotech (XBIT) Receives FDA Nod for V-SPINE Study - GuruFocus
XBiotech clears FDA review for axial spondyloarthritis study - Investing.com
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - Yahoo Finance UK
XBiotech Inc. (XBIT) Holds Near Support Amidst Minor DeclinesDescending Triangle - newsline.com
XBIT Should I Buy - Intellectia AI
XBiotech Inc stock (US9840001002): shares little changed as investors await next earnings update - Ad-hoc-news.de
XBiotech Inc. (XBIT) Slips 2.27% as Stock Tests Key Support LevelsMotive Wave - The Legal Advocate
XBITXBiotech Inc Dividends - Finviz
XBiotech Inc. (XBIT) Edges Higher, Approaching Key Resistance at $2.56Trading Ideas - The Legal Advocate
XBiotech Inc. (XBIT) Edges Higher on Modest Volume, Tests Resistance Near $2.58Composite Profile - The Legal Advocate
XBiotech (XBIT) Edges Lower as Stock Tests Key Support LevelFloat Adjusted Cap - dars.gov.et
XBIT | XBiotech Inc Insider Trading - Quiver Quantitative
Xbiotech Inc (XBIT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):